Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CEO AND PRESIDENT

CHIEF SCIENTIFIC OFFICER

CHIEF MEDICAL OFFICER

PRINCIPAL ACCOUNTING OFFICER

CHIEF FINANCIAL OFFICER

CHIEF BUSINESS OFFICER

CEO and President

Chief Scientific Officer

Chief Business Officer

Chief Medical Officer

Chief Commercial Officer

Chief Financial Officer

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, inf...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-28	Premium	sold	Premium	Premium	Premium	-
2024-03-28	Premium	bought	Premium	Premium	Premium	-
2024-03-27	Premium	bought	Premium	Premium	Premium	-
2024-03-26	Premium	acquired	Premium	Premium	Premium	CEO AND PRESIDENT
2024-03-26	Premium	acquired	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-03-26	Premium	bought	Premium	Premium	Premium	-
2024-03-14	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-14	Premium	sold	Premium	Premium	Premium	PRINCIPAL ACCOUNTING OFFICER
2024-03-14	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-14	Premium	sold	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-03-14	Premium	sold	Premium	Premium	Premium	CHIEF BUSINESS OFFICER
2024-03-14	Premium	sold	Premium	Premium	Premium	CEO AND PRESIDENT
2024-03-13	Premium	sold	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	CHIEF BUSINESS OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	PRINCIPAL ACCOUNTING OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	CEO AND PRESIDENT

IGMS - IGM Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IGMS